Revolution Medicines’ pancreatic cancer drug Rasonque (daraxonrasib) may have breezed through a regulatory approval in the US, but rolling out the treatment across patient groups remains complex.
Speaking at the Jefferies Global Healthcare Conference in London on 16 November, RevMed’s CEO Mark Goldsmith said that whilst Rasonque’s launch has a steep trajectory, it has had “substantial complexity” because of an expanded access programme.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Rasonque is one of oncology’s biggest success stories this year. Phase III results from the RASolute 302 study (NCT06625320) demonstrated that patients with unsuccessfully treated pancreatic adenocarcinoma who took Rasonque lived for a median of 12.4 months, compared with 6.7 months for those treated with chemotherapy.
The drug was subsequently approved by the US Food and Drug Administration (FDA) in August and has been recommended for approval in Europe.
RevMed’s Rasonque works by inhibiting RAS, a protein that plays an important role in cell growth and survival. In cancer patients, mutations in the RAS gene cause these proteins to be permanently active, leading to uncontrolled cell growth. The drug blocks the protein’s activity, which kills cancer cells and slows metastasis.
A section of patients who were unable to participate in the 302 study were able to access the drug through the FDA’s expanded access programme.
“It was a very healthy expanded access programme, one of the fastest with great uptake. There were more than 2,000 patients in that programme, and many of those patients did transition over to the commercial drug,” Goldsmith said.
The second group were those who were not in the access programme and thus were waiting to start taking the drug – many of these were late-stage pancreatic cancer patients.
“Some of those patients were even on hospice care, and once the drug was available, were given an opportunity to take something that was highly differentiated from the options that they had already used up,” Goldsmith commented.
These two groups, the executive added, are a one-time population. The third group – those previously treated but who have not advanced to third or fourth line – will form the core population of the drug’s commercialisation going forward.
RevMed reported that Rasonque generated $197.6m in net product revenue during its Q3 earnings. Analysts have called the early uptake positive.
“We didn’t break down the details of who those patients were, largely because there aren’t patterns that are easily recognisable at this point in time. There’s just too much variability. As things begin to stabilise, we’ll provide more information as we get into a more stable growth pattern,” Goldsmith added.
Shares in Revolution have skyrocketed this year on the back of trial readouts and regulatory wins. Full data from RASolute 302 was first presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where it quickly became the landmark session of the event. The results prompted a standing ovation from the audience, moving some oncologists in attendance to tears.
In mid-October, William Blair analysts said in a research note: “We believe Rasonque is the new standard of care in second-line pancreatic cancer, and the launch is set up well.”
Pricing and reimbursement have not been decided yet, with decisions taking place on a country-by-country basis. The list price of Rasonque in the US is $39,800 for a month’s supply.
RevMed is also actively targeting first-line pancreatic cancer, and its pipeline has late-stage studies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
